We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

SYSMEX-EUROPA

Sysmex Europe designs and produces laboratory and hematology diagnostic solutions, including instruments, reagents, c... read more Featured Products: More products

Download Mobile App




Prospective Blood Donors Deferred by Hemoglobin Estimation Methodology

By LabMedica International staff writers
Posted on 13 Dec 2015
Blood transfusion is an essential part of health care and permits increasingly complex medical and surgical interventions and dramatically increases the life expectancy and quality of life of patients with a variety of acute and chronic conditions. More...


In developing countries, it is believed that a large majority of donor deferral could be due to a temporal and correctable cause such as anemia which is a condition of less than normal levels of healthy red blood cells circulating in the blood stream and the severity of anemia is measured by a person’s hemoglobin level.

Medical laboratory scientists at the University of Ghana (Accra) determined anemia in prospective blood donors deferred by the copper sulphate technique of hemoglobin estimation. Venous blood samples were collected into anticoagulant tubes from the subjects who were consenting potential blood donors but failed to meet the requirement for donation due to low hemoglobin level using the copper sulphate technique. The hemoglobin levels and red cell indices were measured using an automatic hematology analyzer. A thin blood film was prepared and stained using Leishman stain and then observed under the light microscope.

A total number of 1,263 prospective blood donors presented to donate blood during the period of this study. Out of these, 1,120 (88.68%) were males and 143 (11.32%) females. A total of 538 (42.6%) involving 444 males and 94 females were deferred due to varied reasons and 114 (21.2%) of these were due to low hemoglobin (Hb) level. These were assessed for anemia using Hb and red cell indices from a Sysmex 2000i hematology autoanalyzer (Sysmex Corporation; Kobe, Japan) and morphology. Those with Hb less than 13.5 g/dL for males and Hb less than 12.0 g/dL for females were termed as anemic.

Ninety two of the 114 (80.7%) were eventually diagnosed with various forms of anemia using the standard methods of full blood count and morphology. This represented 17.1% of the total number (538) deferred and 7.3% of the total (1,263) prospective donors. Twenty two or 19.3% of those who failed the copper sulphate test were found not to be anemic. Four different types of anemia based on the red cell indices and morphology studies were found in the participants who were diagnosed with anemia. These were normocytic normochromic, normocytic hypochromic, microcytic normochromic and microcytic hypochromic.

The authors concluded that there was a high prevalence of deferral of prospective blood donors and a significant proportion of these deferred donors were as a result of low Hb levels and subsequently anemia. They suggest that people who fail the copper sulphate procedure of Hb testing should not be just sent way as deferred donors but rather be assessed for anemia and be offered advice and treatment so that if their anemia can be corrected, they are encouraged to come back to donate. The study was published on October 22, 2015, in the journal BMC Hematology.

Related Links:

University of Ghana 
Sysmex Corporation



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.